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A Tale of Two Techniques: Demystifying the Myth
M. Fuad Jan, MBBS, MD │ Editorial
Aurora Cardiovascular Services, Aurora Health Care, Milwaukee, WI

It was the best of times, it was the worst of times,
it was the age of wisdom, it was the age of foolishness,
it was the epoch of belief, it was the epoch of incredulity,
it was the season of Light, it was the season of Darkness,
it was the spring of hope, it was the winter of despair,
we had everything before us, we had nothing before us,
we were all going direct to Heaven, we were all going
direct the other way. . . .
-A Tale of Two Cities, by Charles Dickens
Forty-eight years since the introduction of coronary
artery bypass surgery (CABG) in 19671 and 38
years after the first reported percutaneous coronary
intervention (PCI) in a human in 1977,2 the battle for
supremacy between cardiac surgery and interventional
cardiology as the preferred treatment modality
for complex coronary artery disease (CAD) ––
specifically, three-vessel or multivessel disease (3VD)
with or without unprotected left main coronary artery
disease (ULMCA) –– shows no signs of receding.3-6
Interventional cardiologists have made rapid additions
to their armamentarium for treating complex CAD
through the development of newer-generation drugeluting stents (DES) and novel antithrombotic
drugs. At the same time, cardiac surgeons have
improved revascularization procedures through the
implementation of bilateral left internal mammary
artery grafts as well as off-pump and minimally
invasive surgery.
Before SYNTAX
Historically, numerous randomized and multicenter
studies (e.g. ERACI, EAST, GABI, CABRI, MASS,
BARI, SIMA, LAUSANNE, RITA and TOULOUSE)7
demonstrated the superiority of CABG over PCI

Correspondence: M. Fuad Jan, MBBS, MD, 2801 W. Kinnickinnic River Parkway, Suite 840, Milwaukee, WI, 53215,
T: 414-649-3909, F: 414-649-3551, Email:
publishing18@aurora.org
Editorial

(mainly
percutaneous
transluminal
coronary
angioplasty at that time), which led to the abandonment
of balloon angioplasty and the emergence of new
stents. In this more recent era (up to 2009), the results
of percutaneous transluminal coronary angioplasty
and stenting with bare-metal stents were compared
in multiple studies (e.g. AWESOME, ARTS, SOS,
ERACI, MASS, among others). Although the results
in the first year were similar for patients treated with
either surgery or stent, at 5 years, the reoperations in
the stent group were higher due to multiple restenoses,
reaffirming that CABG was the better option for patients
with 3VD/ULMCA disease. Almost all of these studies
were criticized, as they included a very small number
of randomized patients (~5%) and few patients with
ULMCA,7 inconsistent with real-world experience.
After SYNTAX
In 2009, the 1-year results of the SYNTAX trial8,9
prepared the contemporary framework in which
patients with 3VD/ULMCA are now evaluated. This
randomized, prospective, multicenter trial (85 centers in
18 countries) incorporated an “all-comers” design and
consisted of patients with ULMCA disease (isolated
or associated with one to three vessels) or de novo
3VD. Patients were randomized on a 1:1 basis to either
CABG or PCI with a paclitaxel-eluting stent (TAXUS
Express, Boston Scientific Corp., Natick, MA) or
placed in nested registries when considered unsuitable
for randomization by the Heart Team (i.e. a CABG
nested registry for PCI-ineligible patients and a PCI
nested registry for CABG-ineligible patients). CABG
techniques between the randomized and nested registry
were broadly similar, except that double left and right
internal mammary artery grafts were more frequently
performed in the randomized CABG population
(27.6%) than in the CABG nested registry (16.1%). Of
the 589 stents implanted within the PCI nested registry,
57% were the TAXUS Express, 19% were another
paclitaxel-eluting stent and 24% were bare-metal. Four
PCI-nested patients did not receive a stent.
www.aurora.org/jpcrr
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The “final episode” of this landmark trial was released
in 2013.10 The primary endpoint was noninferiority
of PCI with paclitaxel-eluting stent versus CABG for
the incidence of major adverse cardiovascular and
cerebrovascular events (MACCE) at 12 months. At
5-year follow-up, CABG was associated with lower
rates of MACCE (37.5% vs. 24.2%, P<0.01), death
(14.6% vs. 9.2%, P<0.01), myocardial infarction
(10.6% vs. 3.3%, P<0.01) and repeat revascularization
(25.4% vs. 12.6%, P<0.01) compared with PCI. No
difference in the rate of stroke was observed between
the groups (3.0% vs. 3.4%, P=0.66). The final 5-year
follow-up in patients with ULMCA disease also was
published.11 In contrast to patients with 3VD, no
significant differences in MACCE were observed
between PCI and CABG in patients with ULMCA
disease (36.9% PCI vs. 31% CABG, P=0.12). However,
CABG was associated with an increased rate of stroke
(5% vs. 14%, P=0.03), which was counterbalanced by
a higher revascularization rate in the PCI group (26.7%
vs. 15.5%, P<0.01). After stratification for SYNTAX
score tertiles, an increase in survival was observed in
PCI-treated patients with a score ≤ 32. Conversely,
CABG was associated with a reduced incidence of
MACCE in patients with a score > 32.
The anatomical SYNTAX score, with low (<23),
intermediate (23–32) or high (>32) categories,8,12
became a sentinel tool in the SYNTAX trial and
pioneered the now-popular “Heart Team” approach, in
which a cardiac surgeon and interventional cardiologist
determine the optimal revascularization modality for
patients with 3VD/ULMCA disease. It combines the
importance of diseased vessel segment weighting
(Leaman score), adverse lesion characteristics
(American College of Cardiology/American Heart
Association lesion classification, and total occlusion
characteristics from the European TOTAL Surveillance
Study) and the Medina classification system for
bifurcation lesions.13-16 However, the SYNTAX score
is open to criticism since it relies solely on scoring
coronary anatomy and does not take potentially
important prognostic information into consideration
in the absence of clinical factors.17,18 Consequently,
several risk stratification tools have attempted to
merge the SYNTAX score with clinically based risk
scores to improve the risk stratification of patients
with 3VD/ULMCA disease undergoing CABG or PCI
88
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compared with the SYNTAX score alone. Examples
include the Clinical SYNTAX score (a combination
of the SYNTAX score and the modified ACEF score
[i.e. age/ejection fraction + 1 point for every 10 ml/
min reduction in creatinine clearance below 60 ml/
min/1.73 m2 (up to a maximum of 6 points)]), the
Global Risk score (a combination of the SYNTAX
score and EuroSCORE) and the EuroHeart score.18-27
The latest addition to this risk stratification mélange
is the SYNTAX score II, which includes a nomogram
for bedside application to obtain long-term mortality
predictions for individual patients considering CABG
or PCI.28 This score, which was externally validated
in the multinational DELTA (n=2,891) and CredoKYOTO (n=3,896) registries,8,29 consists of two
anatomical (SYNTAX score and ULMCA disease) and
six clinical (age, creatinine clearance, left ventricular
ejection fraction, sex, chronic obstructive pulmonary
disease and peripheral vascular disease) variables.
Unlike the anatomical SYNTAX score, which is more
predictive of clinical outcomes in patients undergoing
PCI than in those undergoing CABG, for whom it is
not predictive,18,30 the SYNTAX score II provides
individual mortality predictions for both CABG and
PCI in addition to a measure of the magnitude of
their differences, with clinically applicable accuracy.
Currently, validation of the SYNTAX score II is a
prespecified endpoint in the ongoing randomized
EXCEL trial (NCT01205776) and the planned
SYNTAX II trial, both of which will use SYNTAX
score II to recruit patients on the grounds of patient
safety. Early findings indicate the SYNTAX score
II is equally predictive for long-term mortality
between CABG and PCI in subjects with ULMCA
disease up to an intermediate anatomical complexity.
Both anatomical and clinical characteristics had a
clear impact on long-term mortality predictions and
decision-making between CABG and PCI.31
In this issue of Journal of Patient-Centered Research
and Reviews, Nfor et al.32 report on the clinical
outcomes after PCI with newer-generation DES
(everolimus or zotarolimus in ~80% patients) versus
CABG in 3VD/ULMCA on a nonrandomized “high
risk” surgical cohort of select patients in their tertiary
care institution. These patients were identified as
“high risk” based on Society of Thoracic Surgeons
Editorial

(STS)-predicted operative mortality of > 5%. Of note,
approximately 40% of this cohort had an STS score
≥ 15, qualifying them to be considered “extreme
risk.” Although, the mean STS score between the PCI
and CABG groups did not significantly differ, more
patients revascularized with PCI fell in the extreme
risk category (63.9% vs. 28.9%, P<0.001). Mean age
of the population in the study was 77 ± 9 years with
42% of these being above the age of 80 years. In this
high-risk surgical population there was no significant
difference in the mean SYNTAX score between the PCI
and CABG groups (37.0 ± 12 vs. 40.0 ± 15, P=0.12).
Given these characteristics of the population, it is quite
evident the investigators were dealing with a subset of
patients with advanced atherosclerotic cardiovascular
disease demanding excellent clinical acumen and
technical skills to achieve the best possible means of
revascularization.
After a mean follow-up of approximately 3 years, the
primary endpoint, a composite of death, myocardial
infarction or stroke, occurred in 42.2% of PCI
patients and 39.6% of CABG patients, an insignificant
difference. The investigators also report no differences
in the individual components of the primary endpoint
between PCI and CABG as well as MACCE rates
(50.6% in PCI group vs. 42.2% in CABG group,
P=0.23). However, the authors do report a threefold
higher incidence of repeat revascularization in the PCI
group compared with the CABG group.
The authors chose to retrospectively apply the STS risk
model33,34 to predict the risk of operative mortality and
morbidity after adult cardiac surgery based on patient
demographic and clinical variables. It is the most
frequently used risk profile system in the United States
and comprises more than 40 preoperative variables
stratifying patients into low risk (STS score ≤3),
intermediate risk (>3–8) and high risk (>8). Although
the STS score does not include variables like frailty,
malnutrition, porcelain aorta and liver disease, and the
cut-off STS scores may be arbitrary at best, it continues
to be the best stratification process at present. The
authors conclude that in patients with 3VD/ULMCA
and STS score > 5%, PCI or CABG are similar with
respect to long-term death, myocardial infarction or
stroke, irrespective of individual SYNTAX scores.

Editorial

These findings appear to contradict the landmark
SYNTAX trial, the results and impact of which
have already been detailed. These findings also are
in contrast to a substudy of the SYNTAX trial18 that
suggested patients with high clinical comorbidity, i.e.
additive EuroSCORE ≥ 6 with 3VD irrespective of
the anatomical complexity (SYNTAX score),19 might
derive a prognostic benefit from undergoing CABG
rather than PCI provided an acceptable threshold of
operative risk is not exceeded.
The combination of angiographic and clinical profiles
allows clinicians to consider that PCI in subjects
with ULMCA disease and a low-risk anatomical
profile may be associated with a prognostic benefit,
whereas more complex disease and a higher-risk
clinical profile would remain the domain of CABG
on the grounds of prognosis. Anatomical complexity
of CAD can vary from a single lesion in the shaft
of the left main coronary artery to distal trifurcation
disease or involve left main disease with more
complex downstream (three-vessel) disease. These
variances may influence the capacity of PCI to achieve
complete revascularization, the number of stents
implanted and complexity of interventional techniques
employed. Moreover, incomplete revascularization
and anatomical complexity (residual SYNTAX score)
have been directly correlated to late all-cause mortality
following PCI.11,35,36 This was demonstrated in the PCI
arm of the ULMCA subgroup of SYNTAX, for which
the incidence of 5-year all-cause mortality was shown
to markedly increase in subjects with a SYNTAX
score ≥ 33 (5-year mortality of 20.9%) compared with
subjects with a SYNTAX score < 33 (5-year mortality
of 7.9%). Conversely, in subjects undergoing CABG,
anatomical complexity was shown to not affect longterm prognosis, as exemplified in the CABG arm of
the ULMCA subgroup of SYNTAX, for which the
incidence of 5-year all-cause mortality remained almost
unchanged in subjects with a SYNTAX score ≥ 33 (5year mortality of 14.1%) compared with subjects with
a SYNTAX score < 33 (5-year mortality of 15.1%).11
SYNTAX in the Contemporary Era
It is important to note that improved clinical outcomes
with the everolimus-eluting stent –– the most used
stent in Nfor et al.’s study (~59%32) –– in multivessel
disease,37 coupled with similarly reported data from the
www.aurora.org/jpcrr
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French Left Main Taxus and LEMAX registries that
investigated left main stenting with everolimus-eluting
stents38,39 and the known reductions in stent thrombosis
of newer-generation DES,40-47 implies that if newergeneration DES had been used in the SYNTAX trial,
there would have been a significant reduction in repeat
revascularization and myocardial infarction. It is also
plausible that reductions in mortality would have been
seen with the newer-generation DES.47 Thus, because
the SYNTAX trial used the first-generation paclitaxeleluting stent exclusively, it is not inconceivable that
contemporary PCI using everolimus stents may
outperform results of paclitaxel since randomized
comparisons of everolimus- versus paclitaxel-eluting
stents have consistently shown everolimus to be
associated with more favorable outcomes.45,48-50 In
addition, the largest patient population meta-analysis
(N=4,989) of the SPIRIT clinical program showed that
everolimus-eluting stents were superior to paclitaxeleluting stents in reducing all-cause mortality (3.2%
vs. 5.1%, hazard ratio: 0.65, 95% confidence interval:
0.49–0.86, P=0.003).51 However, in the SYNTAX
trial, if the cardiac mortality events related to stent
thrombosis (as defined by Academic Research
Consortium52) were removed, there would have been
only a modest reduction in cardiac mortality at 5
years: 9% to 8.5% for definite stent thrombosis, and
9% to 7.5% for definite or probable stent thrombosis.53
The main hypothesis behind this is that bypass grafts
protect coronary vessels from future myocardial
infarctions for the lifespan of the graft, particularly
in more complex CAD for which the plaque burden
and risk of future myocardial infarction is potentially
higher than in less complex CAD. Conversely, stents
would only treat individual lesions.18,54
Thus, the potential reduction in mortality with newergeneration DES in the SYNTAX trial would be unlikely
to bridge the gap between CABG and PCI, particularly
with more complex CAD.55 This is exemplified in
the SYNTAX score II, which identifies subsets of
patients across all tertiles of the SYNTAX score who
would have a mortality benefit from undergoing one
type of revascularization over the other. It should be
emphasized that increased anatomical complexity,
particularly in subjects with 3VD, led to a greater
mortality benefit with CABG as opposed to PCI.55
Investigators in the EXCEL trial recruited 1,905
90

JPCRR • Volume 2, Issue 3 • Summer 2015

patients with left main disease and mild-to-moderate
anatomical complexity (SYNTAX score ≤32) and
randomly assigned them to undergo either PCI with
second-generation DES or CABG surgery. This study
could be pivotal in providing support for the efficacy
and safety of PCI in this lesion type.
With consistent improvement in PCI outcomes, a
wider spectrum of patients with complex CAD is
being treated in this fashion. Currently, both European
and North American guidelines recommend PCI as a
valuable treatment option for patients with ULMCA
disease and as an alternative to CABG in patients
with less complex 3VD (SYNTAX score <23).56,57 For
prudent decision-making, it is essential to consider the
risk/benefit ratio of PCI and CABG for 3VD, weighing
procedural invasiveness and associated short-term
complications against the long-term event rates of
death, myocardial infarction, repeat revascularization
and health-related quality of life.
Striking a Balance
The clinician must never underestimate the role of the
individual patient and his or her personal preferences or
perception of risk related to CABG and PCI. Individual
patients may value the risk/benefit trade-off between
CABG and PCI differently. Remaining active in their
professional/personal lives may be vital for some.
Those people would thus be more prepared to accept
the longer-term risks of PCI (in particular an increased
risk of repeat revascularization) compared to the
short-term morbidity effects associated with the more
invasive nature of CABG in order to obtain short-term
pain relief and a rapid return to full mobility.58,59 Others
may prefer to endure short-term pain to obtain a higher
probability of avoiding a subsequent revascularization.
Some patients may prefer to risk undergoing multiple
PCI procedures compared with a single CABG, or they
may prefer to undergo CABG initially to avoid the risk
of requiring CABG subsequent to PCI. Consequently,
from the patient’s perspective, the balance between
these conflicting considerations plays a crucial role
in selecting the preferred revascularization strategy.
Applying this concept to quantify the trade-off between
the risks and benefits of PCI versus CABG (such as
freedom from chest pain and improvement in healthrelated quality-of-life measures) for patients with
multivessel disease, it was recently shown for the first
Editorial

Figure 1. The balancing act between CABG and PCI. The fundamental principal behind revascularization of coronary artery disease in patients with multivessel disease and/or unprotected left main disease should not be viewed
as a principal of war between the two strategies (as in A Tale of Two Cities). Revascularization should be viewed as a
continuum of the evolution of the best possible strategy wherein patient preferences are taken into account. International guidelines, particularly those from the American College of Cardiology, American Heart Association and European Society of Cardiology, aim to be balanced, practical, patient-oriented and evidence-based, and should form the
general framework of local, regional and national protocols for revascularization. Practice should regularly be audited
to ensure best practices. There are clearly trade-offs between the two revascularization strategies that need to be discussed with patients as part of the shared decision-making process. The early hazard of CABG (risk of stroke) may be
unacceptable to some patients, whereas others might want to avoid the later hazards of PCI (risk of needing a repeat
PCI or having a myocardial infarction). The decision also should take into account whether complete revascularization
with PCI appears to be feasible (i.e. residual SYNTAX score).

time that it is possible to quantify a level of risk that
a patient would be able to accept in order to maintain
present functional state.60
To achieve a reasonable balance in the clinical approach
to revascularization of multivessel disease, key factors
in decision-making will require a Heart Team to weigh
patient wishes, approved guidelines, local expertise
and skills, available resources, and regional medical,
Editorial

legal and ethical considerations (Figure 1). Therefore,
risk stratification (SYNTAX, SYNTAX II, STS,
euroSCORE, etc.) should be used only as a guide;
clinical judgment and review by a Heart Team remain
indispensable. Finally, surgeons and interventional
cardiologists should remember that ongoing optimal
medical therapy and risk-factor management is
essential for the best long-term prognosis after CABG
surgery or PCI.
www.aurora.org/jpcrr

91

Whether the preferred revascularization modality will
change with advances in technology is the subject of
ongoing and future trials. In both the EXCEL trial and
the SYNTAX II trial, the SYNTAX score and SYNTAX
score II, respectively, are being used to recruit subjects
on the grounds of patient safety. Further study will
continue to delineate the boundaries between CABG
and PCI to best define the optimal revascularization
modality for individual patients with complex CAD.
Irrespective of the results of these trials, it should
be emphasized that treatment recommendations for
patients with complex CAD need to be undertaken
in the context of the multidisciplinary Heart Team,
in open dialogue with the patient, rather than by an
individual practitioner. This is because individual
patient perceptions of short- and long-term risk are
important factors in decision-making. The goal should
be to fit the patient with the best technique, not to
force the patient into the technique. To paraphrase
Hippocrates: It is more important to know what sort of
person has a high SYNTAX or STS score than to know
what sort of SYNTAX or STS score a person has.
Conflicts of Interest
None.
REFERENCES

1. Favaloro RG, Effler DB, Groves LK, Fergusson DJ, Lozada
JS. Double internal mammary artery-myocardial implantation.
Clinical evaluation of results in 150 patients. Circulation.
1968;37:549-55. CrossRef
2. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative
dilatation of coronary-artery stenosis: percutaneous
transluminal coronary angioplasty. N Engl J Med. 1979;301:618. CrossRef
3. Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary
artery bypass grafting vs percutaneous coronary intervention
and long-term mortality and morbidity in multivessel disease:
meta-analysis of randomized clinical trials of the arterial
grafting and stenting era. JAMA Intern Med. 2014;174:22330. CrossRef
4. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al.
Comparative effectiveness of revascularization strategies. N
Engl J Med. 2012;366:1467-76. CrossRef
5. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J,
Hannan EL. Everolimus-eluting stents or bypass surgery for
multivessel coronary disease. N Engl J Med. 2015;372:121322. CrossRef
6. Park SJ, Ahn JM, Kim YH, et al. Trial of everolimus-eluting
stents or bypass surgery for coronary disease. N Engl J Med.
2015;372:1204-12. CrossRef
7. Soran O, Manchanda A, Schueler S. Percutaneous coronary
intervention versus coronary artery bypass surgery in

92

JPCRR • Volume 2, Issue 3 • Summer 2015

8.

9.

10.

11.

12.
13.
14.

15.
16.

17.
18.

19.
20.

21.

22.

23.

multivessel disease: a current perspective. Interact Cardiovasc
Thorac Surg. 2009;8:666-71. CrossRef
Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous
coronary intervention versus coronary-artery bypass
grafting for severe coronary artery disease. N Engl J Med.
2009;360:961-72. CrossRef
Ong AT, Serruys PW, Mohr FW, et al. The SYNergy between
percutaneous coronary intervention with TAXus and cardiac
surgery (SYNTAX) study: design, rationale, and run-in phase.
Am Heart J. 2006;151:1194-204. CrossRef
Mohr FW, Morice MC, Kappetein AP, et al. Coronary
artery bypass graft surgery versus percutaneous coronary
intervention in patients with three-vessel disease and left main
coronary disease: 5-year follow-up of the randomised, clinical
SYNTAX trial. Lancet. 2013;381:629-38. CrossRef
Morice MC, Serruys PW, Kappetein AP, et al. Five-year
outcomes in patients with left main disease treated with
either percutaneous coronary intervention or coronary artery
bypass grafting in the synergy between percutaneous coronary
intervention with taxus and cardiac surgery trial. Circulation.
2014;129:2388-94. CrossRef
Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX
Score: an angiographic tool grading the complexity of
coronary artery disease. EuroIntervention. 2005;1:219-27.
Farooq V, Brugaletta S, Serruys PW. Contemporary and
evolving risk scoring algorithms for percutaneous coronary
intervention. Heart. 2011;97:1902-13. CrossRef
Leaman DM, Brower RW, Meester GT, Serruys P, van den
Brand M. Coronary artery atherosclerosis: severity of the
disease, severity of angina pectoris and compromised left
ventricular function. Circulation. 1981;63:285-99. CrossRef
Medina A, Suárez de Lezo J, Pan M. [A new classification of
coronary bifurcation lesions]. Rev Esp Cardiol. 2006;59:183.
CrossRef
Hamburger JN, Serruys PW, Scabra-Gomes R, et al.
Recanalization of total coronary occlusions using a laser
guidewire (the European TOTAL Surveillance Study). Am J
Cardiol. 1997;80:1419-23. CrossRef
Applegate RJ. Toward better stratification of patients with left
main disease: value of clinical and angiographic-derived risk
scores. JACC Cardiovasc Interv. 2011;4:298-9. CrossRef
Serruys PW. Farooq V, Vranckx P, et al. A global risk approach
to identify patients with left main or 3-vessel disease who
could safely and efficaciously be treated with percutaneous
coronary intervention: the SYNTAX Trial at 3 years. JACC
Cardiovasc Interv. 2012;6: 606-17. CrossRef
Roques F, Michel P, Goldstone AR, Nashef SA. The logistic
EuroSCORE. Eur Heart J. 2003;24:881-2. CrossRef
Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow
S, Salamon R. European system for cardiac operative
risk evaluation (EuroSCORE). Eur J Cardiothorac Surg.
1999;16:9-13. CrossRef
Ranucci M, Castelvecchio S, Menicanti L, Frigiola A,
Pelissero G. Risk of assessing mortality risk in elective cardiac
operations: age, creatinine, ejection fraction, and the law of
parsimony. Circulation. 2009;119:3053-61. CrossRef
Ranucci M, Castelvecchio S; Surgical and Clinical Outcome
Research (SCORE) group. The ACEF score one year after:
a skeleton waiting for muscles, skin, and internal organs.
EuroIntervention. 2010;6:549-53. CrossRef
Capodanno D, Miano M, Cincotta G, et al. EuroSCORE

Editorial

24.

25.

26.

27.

28.

29.

30.
31.

32.

33.
34.

35.

refines the predictive ability of SYNTAX score in patients
undergoing left main percutaneous coronary intervention. Am
Heart J. 2010;159:103-9. CrossRef
Capodanno D, Caggegi A, Miano M, et al. Global risk
classification and clinical SYNTAX (synergy between
percutaneous coronary intervention with TAXUS and cardiac
surgery) score in patients undergoing percutaneous or
surgical left main revascularization. JACC Cardiovasc Interv.
2011;4:287-97. CrossRef
de Mulder M, Gitt A, van Domburg R, et al. EuroHeart
score for the evaluation of in-hospital mortality in patients
undergoing percutaneous coronary intervention. Eur Heart J.
2011;32:1398-408. CrossRef
Farooq V, Vergouwe Y, Räber L, et al. Combined anatomical
and clinical factors for the long-term risk stratification of
patients undergoing percutaneous coronary intervention: the
Logistic Clinical SYNTAX score. Eur Heart J. 2012;33:3098104. CrossRef
Farooq V, Vergouwe Y, Généreux P, et al. Prediction of
1-year mortality in patients with acute coronary syndromes
undergoing percutaneous coronary intervention: validation of
the logistic clinical SYNTAX (Synergy Between Percutaneous
Coronary Interventions With Taxus and Cardiac Surgery)
score. JACC Cardiovasc Interv. 2013;6:737-45. CrossRef
Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical
and clinical characteristics to guide decision making between
coronary artery bypass surgery and percutaneous coronary
intervention for individual patients: development and
validation of SYNTAX score II. Lancet. 2013;381:639-50.
CrossRef
Campos CM, van Klaveren D, Iqbal J, et al. Predictive
performance of SYNTAX Score II in patients with left
main and multivessel coronary artery disease –– analysis of
CREDO-Kyoto registry. Circ J. 2014;78:1942-9. CrossRef
Serruys PW, Onuma Y, Garg S, et al. Assessment of the
SYNTAX score in the Syntax study. EuroIntervention.
2009;5:50-6. CrossRef
Campos CM, van Klaveren D, Farooq V, et al. Long-term
forecasting and comparison of mortality in the Evaluation of the
Xience Everolimus Eluting Stent vs. Coronary Artery Bypass
Surgery for Effectiveness of Left Main Revascularization
(EXCEL) trial: prospective validation of the SYNTAX Score
II. Eur Heart J. 2015;36:1231-41. CrossRef
Nfor T, Shetabi K, Hassan W, et al. Clinical outcomes after
drug-eluting stents versus coronary artery bypass surgery
in high surgical risk patients with left main or three-vessel
coronary artery disease. J Patient-Centered Res Rev.
2015;2:95-103.
Anderson RP. First publications from the Society of Thoracic
Surgeons National Database. Ann Thorac Surg. 1994;57:6-7.
CrossRef
Shahian DM, O’Brien SM, Filardo G, et al. The Society of
Thoracic Surgeons 2008 cardiac surgery risk models: part 1
–– coronary artery bypass grafting surgery. Ann Thorac Surg.
2009;88:S2-22. CrossRef
Farooq V, Serruys PW, Bourantas CV, et al. Quantification
of incomplete revascularization and its association with fiveyear mortality in the synergy between percutaneous coronary
intervention with taxus and cardiac surgery (SYNTAX)
trial validation of the residual SYNTAX score. Circulation.
2013;128:141-51. CrossRef

Editorial

36. Généreux P, Campos CM, Yadav M, et al. Reasonable
incomplete revascularisation after percutaneous coronary
intervention: the SYNTAX Revascularisation Index.
EuroIntervention. 2014 Oct 14 [Epub ahead of print].
37. Ribichini F, Romano M, Rosiello R, et al. A clinical and
angiographic study of the XIENCE V everolimus-eluting
coronary stent system in the treatment of patients with
multivessel coronary artery disease: the EXECUTIVE trial
(EXecutive RCT: evaluating XIENCE V in a multi vessel
disease). JACC Cardiovasc Interv. 2013;6:1012-22. CrossRef
38. Moynagh A, Salvatella N, Harb T, et al. Two-year outcomes
of everolimus vs. paclitaxel-eluting stent for the treatment of
unprotected left main lesions: a propensity score matching
comparison of patients included in the French Left Main
Taxus (FLM Taxus) and the LEft MAin Xience (LEMAX)
registries. EuroIntervention. 2013;9:452-62. CrossRef
39. Farooq V, Serruys PW, Stone GW, Virmani R, Chieffo A,
Fajadet J. Left main coronary artery disease. In: Eeckhout
E, Serruys PW, Wijns W, Vahanian A, van Sambeek M, De
Palma R (eds). Percutaneous Interventional Cardiovascular
Medicine. The PCR-EAPCI Textbook, Volume 2, Part III.
Toulouse, France: PCR Publishing and Europa Edition, 2012,
pp. 407-45.
40. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent
thrombosis with drug-eluting and bare-metal stents: evidence
from a comprehensive network meta-analysis. Lancet.
2012;379:1393-402. CrossRef
41. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term
outcomes with drug-eluting and bare-metal coronary stents:
a mixed-treatment comparison analysis of 117 762 patientyears of follow-up from randomized trials. Circulation.
2012;125:2873-91. CrossRef
42. Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint
results of the EVOLVE trial: a randomized evaluation of a
novel bioabsorbable polymer-coated, everolimus-eluting
coronary stent. J Am Coll Cardiol. 2012;59:1362-70. CrossRef
43. Serruys PW, Farooq V, Kalesan B, et al. Improved safety and
reduction in stent thrombosis associated with biodegradable
polymer-based biolimus-eluting stents versus durable polymerbased sirolimus-eluting stents in patients with coronary artery
disease: final 5-year report of the LEADERS (Limus Eluted
From A Durable Versus ERodable Stent Coating) randomized,
noninferiority trial. JACC Cardiovasc Interv. 2013;6:777-89.
CrossRef
44. Planer D, Smits PC, Kereiakes DJ, et al. Comparison of
everolimus- and paclitaxel-eluting stents in patients with
acute and stable coronary syndromes: pooled results from the
SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus
Eluting Coronary Stent System) and COMPARE (A Trial of
Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for
Coronary Revascularization in Daily Practice) Trials. JACC
Cardiovasc Interv. 2011;4:1104-15. CrossRef
45. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation
everolimus-eluting and paclitaxel-eluting stents in reallife practice (COMPARE): a randomised trial. Lancet.
2010;375:201-9. CrossRef
46. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimuseluting and everolimus-eluting coronary stents. N Engl J Med.
2010;363:136-46. CrossRef
47. Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent
thrombosis and restenosis with unrestricted use of ‘new-

www.aurora.org/jpcrr

93

48.

49.

50.
51.

52.
53.

54.

94

generation’ drug-eluting stents: a report from the nationwide
Swedish Coronary Angiography and Angioplasty Registry
(SCAAR). Eur Heart J. 2012;33:606-13. CrossRef
Gada H, Kirtane AJ, Newman W, et al. 5-year results of a
randomized comparison of XIENCE V everolimus-eluting
and TAXUS paclitaxel-eluting stents: final results from
the SPIRIT III trial (clinical evaluation of the XIENCE V
everolimus eluting coronary stent system in the treatment of
patients with de novo native coronary artery lesions). JACC
Cardiovasc Interv. 2013;6:1263-6. CrossRef
Brener SJ, Kereiakes DJ, Simonton CA, et al. Everolimuseluting stents in patients undergoing percutaneous coronary
intervention: final 3-year results of the Clinical Evaluation of
the XIENCE V Everolimus Eluting Coronary Stent System
in the Treatment of Subjects With de Novo Native Coronary
Artery Lesions trial. Am Heart J. 2013;166:1035-42. CrossRef
Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting
versus paclitaxel-eluting stents in coronary artery disease. N
Engl J Med. 2010;362:1663-74. CrossRef
Dangas GD, Serruys PW, Kereiakes DJ, et al. Meta-analysis
of everolimus-eluting versus paclitaxel-eluting stents in
coronary artery disease: final 3-year results of the SPIRIT
clinical trials program (Clinical Evaluation of the Xience V
Everolimus Eluting Coronary Stent System in the Treatment
of Patients With De Novo Native Coronary Artery Lesions).
JACC Cardiovasc Interv. 2013;6:914-22. CrossRef
Cutlip DE, Windecker S, Mehran R, et al. Clinical end points
in coronary stent trials: a case for standardized definitions.
Circulation. 2007;115:2344-51. CrossRef
Farooq V, Serruys PW, Zhang Y, et al. Short-term and longterm clinical impact of stent thrombosis and graft occlusion in
the SYNTAX trial at 5 years: Synergy Between Percutaneous
Coronary Intervention with Taxus and Cardiac Surgery trial. J
Am Coll Cardiol. 2013;62:2360-9. CrossRef
Taggart DP. Thomas B. Ferguson Lecture. Coronary artery

JPCRR • Volume 2, Issue 3 • Summer 2015

55.

56.

57.

58.

59.
60.

bypass grafting is still the best treatment for multivessel and
left main disease, but patients need to know. Ann Thorac Surg.
2006;82:1966-75. CrossRef
Farooq V, Serruys PW. Complex coronary artery disease:
would outcomes from the SYNTAX (synergy between
percutaneous coronary intervention with taxus and cardiac
surgery) trial have differed with newer-generation drug-eluting
stents? JACC Cardiovasc Interv. 2013;6:1023-5. CrossRef
Task Force on Myocardial Revascularization of the European
Society of Cardiology (ESC) and the European Association
for Cardio-Thoracic Surgery (EACTS); European Association
for Percutaneous Cardiovascular Interventions (EAPCI),
Wijns W, et al. Guidelines on myocardial revascularization.
Eur Heart J. 2010;31:2501-55. CrossRef
Levine GN, Bates ER, Blankenship JC, et al. 2011
ACCF/AHA/SCAI Guideline for Percutaneous Coronary
Intervention: executive summary: a report of the American
College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines and the
Society for Cardiovascular Angiography and Interventions.
Circulation. 2011;124:2574-609. CrossRef
van Domburg RT, Daemen J, Morice MC, et al. Short- and
long-term health related quality-of-life and anginal status
of the Arterial Revascularisation Therapies Study part II,
ARTS-II; sirolimus-eluting stents for the treatment of patients
with multivessel coronary artery disease. EuroIntervention.
2010;5:962-7. CrossRef
Cohen DJ, Van Hout B, Serruys PW, et al. Quality of life
after PCI with drug-eluting stents or coronary-artery bypass
surgery. N Engl J Med. 2011;364:1016-26. CrossRef
Federspiel JJ, Stearns SC, van Domburg R, Sheridan BC, Lund
JL, Serruys PW. Risk-benefit trade-offs in revascularisation
choices. EuroIntervention. 2011;6:936-41. CrossRef

© 2015 Aurora Health Care, Inc.

Editorial

